<DOC>
	<DOCNO>NCT00370292</DOCNO>
	<brief_summary>Patients affect non-small cell lung cancer ( NSCLC ) treat pemetrexed monochemotherapy regimen maximum 8 cycle . Pemetrexed enhancer biomolecules involve gemcitabine mechanism action . Purpose trial monitor blood value biomolecules different time interval , optimize synergism pemetrexed gemcitabine .</brief_summary>
	<brief_title>Dosage Schedule Study Pemetrexed Monochemotherapy Locally Advanced Metastatic Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically proven IIIB IV NSCLC . No symptomatic uncontrolled brain metastasis Not suitable platinum contain regimen chemonaive Performance status less equal 2 Eastern Cooperative Oncology Group ( ECOG ) Scale . Creatinine Clearance ( CrCl ) great equal 45 milliliter per min ( mL/min ) Exclusion Criteria Prior radiation great 25 % bone marrow Inability interrupt Aspirin dose great 1.3 grams/day nonsteroidal antiinflammatory agent 5day period . Presence clinically relevant thirdspace fluid collection controllable . Significant cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>